This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL (NCT05507827), a na phase 1 study. The primary outcome is Number of Patients Who Received Donor CD19/CD22-CAR T Cells.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05507827 |
| Phase | Phase 1 |
| Condition | Lymphoid Leukemia |
| Allocation | Not applicable (single group) |
| Design model | Sequential |
| Masking | None (open label) |
| Enrollment | 22 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Melody Smith |
| Results posted | Yes |
2. Clinical Question
The trial concerns adults with B-cell acute lymphoblastic leukemia who receive myeloablative conditioning and Orca-T, followed by an intended infusion of allogeneic, donor-derived CD19/CD22-CAR T cells. The registry describes the CAR T cells as transduced with a bivalent CD19/CD22 lentiviral vector. Its central clinical question is whether these cells can be manufactured to meet established release specifications and administered in this treatment setting, with safety as the stated focus.
Population
Adults with B-cell acute lymphoblastic leukemia receiving myeloablative conditioning and Orca-T. The condition is also listed as lymphoid leukemia in the registry record.
Intervention
Allogeneic, donor-derived T cells carrying a CD19/CD22 chimeric antigen receptor, following myeloablative conditioning and Orca-T. The registry lists Treg CD34+HSPC as Orca-T.
Comparator
No randomized comparator is listed. Allocation is recorded as NA, and the design is sequential; the dose levels are part of dose escalation, not a like-for-like control comparison.
Primary question
The primary endpoint is the number of patients who received donor CD19/CD22-CAR T cells. The description links this measure to the ability to manufacture cells meeting release specifications; the timeframe is 42 days.
The registry summary also frames the broader safety question around whether the approach can augment graft-versus-leukemia activity without increasing acute graft-versus-host disease or graft failure. These are stated aims, not conclusions established by the posted outcome figures. The registry lists secondary outcomes including disease progression, secondary graft failure, progression-free survival, overall survival and infectious disease complications.
The primary outcome count itself is not reported in the registry record. The record notes that one subject did not receive CAR T infusion because of a current active infection at the time of infusion, but this note does not supply the primary endpoint result. That distinction matters: a reason for not receiving an infusion is not a complete count of participants meeting the endpoint.
3. Trial Design
This is a phase I trial with a sequential design and no masking. Allocation is listed as NA, and the registry describes a Bayesian dose-escalation design for dosing the donor CD19/CD22-CAR T cells. The listed enrollment is 22. The registry status is active, not recruiting. The record lists a start date of 2022-08-18 and a primary completion date of 2025-06-18; these dates do not establish that all follow-up or analyses are complete.
The treatment approach combines myeloablative conditioning, Orca-T and allogeneic donor-derived CAR T cells. The intended CAR T product targets CD19 and CD22 using a bivalent receptor construct. Orca-T is listed as Treg CD34+HSPC. The primary outcome description indicates that manufacturing a product meeting established release specifications is central to whether infusion can occur. The registry also reports that one subject did not receive infusion because of active infection at the time of infusion.
Sequential dose escalation differs from a randomized trial. In a randomized comparison, participants are assigned to treatment groups under a planned allocation process; here, the registry does not describe random allocation or a control arm. Dose levels therefore should not be interpreted as concurrent treatment and control groups. Differences in event counts between dose levels can reflect the small groups, the sequence of enrollment and other differences in who entered each level, in addition to any relationship with dose. The registry does not report enough information to separate those influences.
The phase I designation and the registry’s safety objective place emphasis on experience with the approach and on dose escalation, rather than on a definitive efficacy comparison. However, the precise dose-escalation rules, dose-limiting toxicity definition, observation window for escalation decisions and stopping criteria are not reported in the registry record. The record also does not report whether the listed enrollment is a planned target or the final number enrolled. Those details should not be inferred from the design label alone.
The registry lists seven outcome measures and no statistical analyses. It names secondary outcomes of disease progression, secondary graft failure, progression-free survival, overall survival and infectious disease complications. Results for these secondary outcomes are not included in the registry record. A named outcome is not itself evidence that its result is available or that it was analyzed in a particular way.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Dose Level 1 | Dose Level 2 | Dose Level 3 | Healthy Donors |
|---|---|---|---|---|
| STARTED | 3 | 3 | 11 | 5 |
| COMPLETED | 3 | 3 | 11 | 5 |
| NOT COMPLETED | 0 | 0 | 0 | 0 |
Analysis population for the primary outcome, as defined in the registry: One subject did not receive CAR T infusion due to current active infection at the time of infusion.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Dose Level 1 | Dose Level 2 | Dose Level 3 | Healthy Donors | Total |
|---|---|---|---|---|---|---|
| Participants analysed | 3 | 3 | 11 | 5 | 22 | |
| Age, Customized: 18 to 29 | Participants | 1 | 2 | 2 | 1 | 6 |
| Age, Customized: 30 to 39 | Participants | 1 | 1 | 3 | 1 | 6 |
| Age, Customized: 40 to 49 | Participants | 1 | 0 | 2 | 1 | 4 |
| Age, Customized: 50 to 59 | Participants | 0 | 0 | 3 | 1 | 4 |
| Age, Customized: 60 to 69 | Participants | 0 | 0 | 1 | 1 | 2 |
| Sex: Female, Male: Female | Participants | 2 | 2 | 5 | 5 | 14 |
| Sex: Female, Male: Male | Participants | 1 | 1 | 6 | 0 | 8 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 1 | 0 | 2 | 1 | 4 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): White | Participants | 0 | 2 | 3 | 2 | 7 |
| Race (NIH/OMB): More than one race | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 2 | 1 | 6 | 2 | 11 |
| Region of Enrollment: United States | participants | 3 | 3 | 11 | 5 | 22 |
6. Primary Endpoint
The registry lists the primary outcome as Number of Patients Who Received Donor CD19/CD22-CAR T Cells, measured over 42 days.
| Element | Registry entry |
|---|---|
| Result type | Count Of Participants |
| Measure of spread | not applicable |
| Unit | Participants |
| Endpoint classification | Binary Endpoint |
The primary endpoint is titled “Number of Patients Who Received Donor CD19/CD22-CAR T Cells.” It is a participant count, with a stated timeframe of 42 days. The outcome description says the measure will be assessed by the ability to manufacture donor CD19/CD22-CAR T cells that meet established release specifications. In this setting, the endpoint connects product availability and release criteria with the ability to proceed to infusion.
A count is a direct descriptive measure: it records how many participants meet the endpoint rather than estimating a comparative treatment effect. In a phase I study, such a measure can describe feasibility alongside the safety objective. It does not, by itself, establish why a participant did or did not receive an infusion, nor does it show whether the intervention changes disease outcomes.
The registry record does not report the primary endpoint count. It notes that one subject did not receive CAR T infusion because of a current active infection at the time of infusion. That explanation is relevant to interpreting receipt of treatment, but it does not give the total number who received infusion or the number whose product met release specifications. The record does not report how manufacturing failure, product release, or other reasons for non-infusion were classified in the endpoint.
The distinction between manufacturing and infusion is important. A product may meet release criteria while an infusion does not occur for another reason; conversely, a participant count for infusion does not independently reveal the manufacturing outcome for every participant. The posted endpoint description connects these concepts but does not provide further operational details. Consequently, the endpoint’s stated purpose can be explained, but its observed result and the exact handling of each step are not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record identifies a phase I sequential dose-escalation trial with a safety focus. It does not report a randomized comparison. Accordingly, event counts across dose levels are descriptive and should not be interpreted as estimates of a causal difference between doses. The groups are small, and the record does not describe allocation to dose level, adjustment for participant characteristics or a model comparing the levels.
The listed serious-event figures vary across dose levels: Dose Level 1 reports 2 affected among 3 at risk, Dose Level 2 reports 3 among 3, and Dose Level 3 reports 1 among 11. The corresponding “other” event counts are 3 among 3, 3 among 3 and 11 among 11. These counts describe the registry’s categories of participants at risk and affected; they do not show how many separate events occurred in each person, how long participants were observed, or whether an event was caused by treatment. Definitions and event-specific observation periods are not reported in the registry record.
The serious-event terms with the highest listed percentages are Bacteremia, Cystitis and Palmar-plantar erythrodysesthesia syndrome, each at 66.7%. Respiratory Simplex Virus is listed at 33.3%, while Febrile neutropenia and Influenza A are each listed at 9.1%. These are registry-listed percentages for terms, not a comparative risk estimate. The denominator for each term-specific percentage and the method used to derive these figures are not reported in the registry record. The percentages therefore should be read as descriptive entries, not as precise comparative measures.
The primary endpoint is the number of patients who received donor CD19/CD22-CAR T cells within the stated 42-day timeframe, linked to manufacture of a product meeting release specifications. Its observed count is not reported in the registry record. The note that one subject did not receive infusion because of active infection does not establish the complete count or the reason for every participant’s endpoint status. No result for the primary endpoint can be reconstructed from that note without making an unsupported calculation.
The trial’s aims include assessing safety and exploring whether the approach may augment graft-versus-leukemia activity without increasing acute graft-versus-host disease or graft failure. These are aims, not findings. Although the registry names progression and survival outcomes, corresponding results are not reported in the registry record. Thus, the registry entries support a description of design, endpoint intent and posted adverse-event counts, but not a conclusion about efficacy, comparative safety or the overall benefit-risk balance.
Small dose-level groups create substantial uncertainty around any apparent pattern. A count such as 1 affected among 11 at one level cannot be compared directly with 2 among 3 at another as if participants had been randomized to otherwise equivalent groups. The sequential design, different group sizes, possible differences in follow-up and absence of reported adjustment all limit interpretation. These limitations do not invalidate the descriptive counts; they define what those counts can reasonably convey.
No confidence intervals or statistical comparisons are reported in the registry record. Without interval estimates, the precision of the event rates cannot be assessed from the record’s stated analyses. Even when a percentage is displayed, a precise-looking decimal does not guarantee a precise estimate, especially when the underlying group is small or the denominator is unclear. The posted figures are best treated as a safety description within an early-phase study rather than a basis for comparing treatment levels.
9. Statistical Methods Explained
The statistical information in the registry record is limited. It identifies a sequential design and a Bayesian dose-escalation approach for dosing donor CD19/CD22-CAR T cells, but it does not provide the statistical analysis plan, the model details, or the rules used to select a dose. The following concepts explain how such design labels are generally understood; they do not describe unreported trial procedures.
What does sequential dose escalation mean?
In general, a sequential design assigns or considers participants over time rather than placing all participants into treatment groups at once. In dose escalation, experience at one dose level can inform decisions about a subsequent level. The registry identifies a Bayesian approach for dose escalation, but does not report how participant outcomes were translated into a decision, which outcomes informed escalation, or what thresholds governed the process. Those elements cannot be inferred from the word “Bayesian.”
In general, Bayesian methods combine a probability model with information represented through prior distributions and update uncertainty as data accrue. The model can express uncertainty about risks at different doses, but the result depends on the model, the prior assumptions and the observed data. None of those specifics is reported in the registry record. The phrase “Bayesian dose escalation” therefore identifies a broad design approach, not a complete description of the analysis or its operating characteristics.
A sequential design also means that dose levels may be considered at different points in enrollment. General comparisons between levels can be affected by changes in participant mix, clinical practice, follow-up duration or other time-related factors. This does not mean any such change occurred in this trial; it means that without randomization and additional design details, simple differences in observed counts cannot isolate a dose effect. The registry explicitly cautions that the dose groups are not a like-for-like control comparison.
How should participant counts be read?
The primary outcome is a count of participants who received donor CD19/CD22-CAR T cells, with a 42-day timeframe and a description linking the measure to manufacture of cells meeting release specifications. A participant count is a descriptive endpoint. In general, it answers how many people met the stated outcome definition, but interpretation depends on the denominator, eligibility for assessment, and the rules for handling missing or indeterminate status. These endpoint details are not fully reported in the registry record.
The registry notes that one subject did not receive infusion because of a current active infection at the time of infusion. That note gives a reason for one non-infusion, but not the complete participant flow or the primary endpoint value. It does not establish whether the product was manufactured, whether it met release criteria, or how that participant was classified for the endpoint. The count itself is not reported in the registry record.
What can adverse-event counts show?
For Dose Level 1, the serious-event group has 3 at risk and 2 affected; the other-event group has 3 at risk and 3 affected. For Dose Level 2, the corresponding counts are 3 and 3 for serious events, and 3 and 3 for other events. For Dose Level 3, the counts are 11 and 1 for serious events, and 11 and 11 for other events. These are counts of participants, not a count of distinct event episodes. The record does not state whether a participant could contribute to multiple terms or categories, or give the precise definitions behind the categories.
In general, an adverse-event count is descriptive unless a defined comparison, analysis population and follow-up structure support a formal contrast. A person may experience more than one event, and event severity, duration and relationship to treatment are distinct from whether an event was reported. These details are not posted by the counts alone and are not reported in the registry record. The top serious-event terms are listed with percentages, but their denominators and calculation method are not reported.
What do uncertainty and over-dispersion mean generally?
General statistical context: a point estimate is a single summary of an uncertain quantity. A confidence interval, when calculated under a stated method, describes a range of values compatible with the data and method; it is not a guarantee that the true value lies within that interval. No confidence intervals for the adverse-event figures are reported in the registry record. For small groups, interval estimates can be wide, so a displayed percentage should not be mistaken for high precision.
General statistical context: over-dispersion occurs when observed variation is greater than a statistical model assumes. If a model assumes that observations vary only according to a simple binomial process, unaccounted clustering or variation in individual risk can make uncertainty appear smaller than it is. Methods that account for extra variation may be appropriate in some settings. The registry record does not report whether over-dispersion was assessed or whether any particular event model was used; this is a general concept, not a claim about the trial’s analysis.
What are the planning illustrations?
The stated sample-size assumptions describe a planning illustration based on the observed effect, not the trial’s own design. They specify a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation and effects expressed as stated fractions of the observed effect. For time-to-event outcomes, the stated convention is total events; for other outcomes, it is participants per arm. These assumptions should not be confused with the sequential dose-escalation design or with the actual enrollment.
In general, such illustrations ask how much information a hypothetical comparison might need under specified assumptions. They do not show that a study achieved a target probability of detecting an effect, and they are not observed power. In this trial, the record does not describe a randomized two-arm comparison, and the observed primary endpoint result is not reported. The registry record also does not report the trial’s sample-size justification. The planning assumptions therefore should be read as hypothetical context, not as evidence that the trial was designed or powered for a particular comparison.
The registry lists no analyses. It does not report adjusted models, estimation procedures, confidence intervals, hypothesis tests, interim analyses or multiplicity handling. Absence of an analysis listing does not prove that no analyses were conducted; it means those methods are not reported in the registry record. Statistical conclusions should be limited to the descriptive details that are actually posted.
10. Exact Estimates for Each Arm
No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.
| Arm | Participants | Events | Observed % | Clopper-Pearson 95% CI | Wilson 95% CI | Bayesian 95% credible interval |
|---|---|---|---|---|---|---|
| Dose Level 1 | 3 | 3 | 100.0% | 29.2% to 100.0% | 43.9% to 100.0% | 39.8% to 99.4% |
| Dose Level 2 | 3 | 3 | 100.0% | 29.2% to 100.0% | 43.9% to 100.0% | 39.8% to 99.4% |
| Dose Level 3 | 11 | 10 | 90.9% | 58.7% to 99.8% | 62.3% to 98.4% | 61.5% to 97.9% |
R code and output
arm <- c("Dose Level 1", "Dose Level 2", "Dose Level 3")
n <- c(3, 3, 11)
events <- c(3, 3, 10)
for (i in seq_along(n)) {
ci <- binom.test(events[i], n[i])$conf.int # Clopper-Pearson exact interval
cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i]) # Bayesian, uniform Beta(1,1) prior
wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}
ARM Dose Level 1 3 3 100.0 29.2 100.0 43.9 100.0 39.8 99.4
ARM Dose Level 2 3 3 100.0 29.2 100.0 43.9 100.0 39.8 99.4
ARM Dose Level 3 11 10 90.9 58.7 99.8 62.3 98.4 61.5 97.911. Multiplicity, Missing Data and Analysis Populations
The registry names several outcomes: the primary count of patients who received donor CD19/CD22-CAR T cells, along with outcomes concerning disease progression, secondary graft failure, progression-free survival, overall survival and infectious disease complications. It lists seven outcome measures in total. The record does not report a multiplicity strategy, such as a hierarchy of confirmatory tests or an adjustment for testing several outcomes. It also lists no analyses. Without a stated analysis plan, it is not possible to determine which outcomes were intended to support formal inference or how any multiple testing was handled.
The primary endpoint result is not reported in the registry record. The note about one subject who did not receive infusion due to active infection does not establish the complete analysis population. The record does not describe whether the primary endpoint was evaluated among all enrolled participants, only those who received conditioning, or another population. It also does not explain how participants with unavailable manufacturing or infusion information were handled.
Missing-data methods are not reported in the registry record. In general, missingness can affect interpretation when participants without an observed outcome differ from those with recorded outcomes. The extent and pattern of missing data, any imputation approach, and sensitivity analyses are not reported. No assumptions about these matters should be made from the single note about non-infusion.
Analysis populations for safety and efficacy are also not specified. The registry record does not state whether safety summaries include all treated participants, all infused participants, or another group, nor how follow-up time was defined. That information is important because denominators can differ by outcome and because participants may have differing opportunities for an event to be observed. The listed at-risk counts describe the posted adverse-event summaries, but do not substitute for a full population definition.
The record’s status is active, not recruiting, and it lists a primary completion date of 2025-06-18. Neither the status nor the date identifies which analyses are complete or whether all follow-up has concluded. The registry does not report an interim-analysis plan or the timing and purpose of any interim reviews.
12. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Dose Level 1 | 2 | 3 | 66.7% |
| Dose Level 2 | 3 | 3 | 100.0% |
| Dose Level 3 | 1 | 11 | 9.1% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Dose Level 1 | 0 of 3 |
| Dose Level 2 | 0 of 3 |
| Dose Level 3 | 0 of 11 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Dose Level 1 | 3 of 3 |
| Dose Level 2 | 3 of 3 |
| Dose Level 3 | 11 of 11 |
Most frequent serious adverse event terms
| Event term | Organ system | Dose Level 1 | Dose Level 2 | Dose Level 3 |
|---|---|---|---|---|
| Bacteremia | Infections and infestations | 2 of 3 | 1 of 3 | 0 of 11 |
| Cystitis | Renal and urinary disorders | 2 of 3 | 1 of 3 | 0 of 11 |
| Palmar-plantar erythrodysesthesia syndrome | Skin and subcutaneous tissue disorders | 0 of 3 | 2 of 3 | 0 of 11 |
| Febrile neutropenia | Blood and lymphatic system disorders | 0 of 3 | 0 of 3 | 1 of 11 |
| Respiratory Simplex Virus | Infections and infestations | 0 of 3 | 1 of 3 | 0 of 11 |
| Influenza A | Infections and infestations | 0 of 3 | 0 of 3 | 1 of 11 |
| Injection site reaction | Injury, poisoning and procedural complications | 0 of 3 | 0 of 3 | 1 of 11 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Dose Level 1 | Dose Level 2 | Dose Level 3 |
|---|---|---|---|---|
| Platelet count decreased | Investigations | 3 of 3 | 3 of 3 | 11 of 11 |
| White blood cell decreased | Investigations | 3 of 3 | 3 of 3 | 11 of 11 |
| Mucositis oral | Gastrointestinal disorders | 2 of 3 | 3 of 3 | 10 of 11 |
| Diarrhea | Gastrointestinal disorders | 3 of 3 | 3 of 3 | 8 of 11 |
| Nausea | Gastrointestinal disorders | 3 of 3 | 3 of 3 | 8 of 11 |
| Febrile neutropenia | Blood and lymphatic system disorders | 1 of 3 | 3 of 3 | 8 of 11 |
| Vomiting | Gastrointestinal disorders | 3 of 3 | 3 of 3 | 6 of 11 |
| Alanine aminotransferase increased | Investigations | 2 of 3 | 2 of 3 | 8 of 11 |
| Neutrophil count decreased | Investigations | 2 of 3 | 1 of 3 | 9 of 11 |
| Fatigue | General disorders | 3 of 3 | 3 of 3 | 5 of 11 |
Serious events with the highest arm-level rate: bacteremia (66.7%), cystitis (66.7%), palmar-plantar erythrodysesthesia syndrome (66.7%), respiratory simplex virus (33.3%), febrile neutropenia (9.1%).
The registry reports serious and other adverse-event counts by dose level. For serious events, Dose Level 1 lists 3 participants at risk and 2 affected; Dose Level 2 lists 3 at risk and 3 affected; Dose Level 3 lists 11 at risk and 1 affected. For other events, the counts are 3 at risk and 3 affected at Dose Level 1, 3 and 3 at Dose Level 2, and 11 and 11 at Dose Level 3. These are participant counts and should not be read as numbers of separate event episodes.
The listed serious-event terms and percentages are Bacteremia, 66.7%; Cystitis, 66.7%; Palmar-plantar erythrodysesthesia syndrome, 66.7%; Respiratory Simplex Virus, 33.3%; Febrile neutropenia, 9.1%; and Influenza A, 9.1%. The registry record does not report the denominator or calculation method for each term-specific percentage. It also does not provide event-level timing, duration, recurrence, treatment attribution or the relationship between these terms and the dose-level summaries.
These data describe reported adverse events; they do not establish causation or permit a reliable comparison between dose levels. The groups are small and sequential rather than randomized control groups. Definitions of the serious and other categories and the safety analysis population are not reported in the registry record. Counts should therefore be interpreted as a limited descriptive account, not as a complete characterization of safety.
13. What the Result Does, and Does Not, Mean
The posted information establishes that the study is a phase I, sequential dose-escalation trial focused on myeloablative conditioning, Orca-T and donor-derived CD19/CD22-CAR T cells in adults with B-cell acute lymphoblastic leukemia. It gives the intended primary endpoint and selected adverse-event summaries. It also identifies one participant who did not receive CAR T infusion because of active infection at the time of infusion.
The information does not establish the primary endpoint result. The number of patients who received the CAR T cells is not reported in the registry record, and the note about one non-infusion cannot be used to reconstruct that number. Nor does the record provide the results of the named progression, graft failure, progression-free survival, overall survival or infectious disease complication outcomes.
The safety counts do not establish that any event was caused by the intervention, nor do they establish a difference in safety across dose levels. Dose groups are not randomized comparison groups, their sizes differ, and the registry does not report adjusted comparisons or uncertainty intervals. The listed term percentages are descriptive entries whose denominators are not reported. They should not be treated as precise estimates of risk or as a complete summary of all possible adverse effects.
The stated aim of augmenting graft-versus-leukemia activity without increasing acute graft-versus-host disease or graft failure is a research question, not a demonstrated result. The registry entries do not support a conclusion that the approach improves disease control, prevents graft failure, or changes the rate of graft-versus-host disease. They also do not support a general conclusion about treatment benefit or lack of benefit.
In general, early-phase studies can characterize feasibility and identify safety signals that merit further evaluation, while estimates from small groups remain uncertain. That general role does not resolve what this trial found. Interpretation should stay within the scope of the available registry outcomes: design features, the endpoint’s stated purpose, the one documented reason for non-infusion and the posted event counts.
14. Why This Trial Matters Statistically
This trial raises several statistical issues that are especially relevant in early-phase dose escalation. First, the design is sequential and the registry describes Bayesian dose escalation. Decisions in a sequential design may depend on accumulating observations, but the record does not report the model, assumptions or decision rules. Without those details, readers cannot assess how dose decisions were calibrated or how uncertainty was represented.
Second, dose-level summaries can look like comparisons even when the design does not provide a control comparison. Here, allocation is listed as NA, and the registry explicitly cautions that the dose levels are not a like-for-like control comparison. Unequal group sizes and the sequential setting mean that a difference in counts cannot be attributed to dose based on the listed summaries alone.
Third, the primary endpoint combines a clinically practical event—receipt of CAR T cells—with a manufacturing objective tied to release specifications. These are related but not identical steps. The separate roles of product manufacture, release and the decision to infuse are important for defining a complete endpoint and understanding non-infusion. The registry explains one non-infusion due to infection but does not report the endpoint count or full participant flow.
Finally, safety percentages can convey more apparent certainty than small underlying groups warrant, particularly when denominators and analysis methods are not reported. Counts, definitions, follow-up and uncertainty estimates all matter. The registry’s limited analysis information makes descriptive interpretation appropriate and makes clear why a complete statistical analysis plan and endpoint results are needed for stronger conclusions.
15. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The primary endpoint count is not reported in the registry record, despite the endpoint title and description. The note that one subject did not receive infusion because of current active infection gives only a single reason for non-infusion and does not provide a complete participant flow. The record does not clarify how product manufacture, release specifications, infusion or other reasons for non-infusion were operationalized in the endpoint.
The registry does not report the dose-escalation model details, dose-selection rules, dose-limiting toxicity definition, escalation stopping criteria or observation window for decisions. It also does not describe the sample-size justification, analysis plan, interim analyses or statistical methods for the listed outcomes. Although a Bayesian dose-escalation design is identified, that label alone does not specify how the study was conducted or analyzed.
The dose-level safety groups are small and unequal, and the design is sequential rather than randomized. No control group or adjusted comparison is described. The adverse-event summaries do not include confidence intervals, event timing, duration, recurrence, attribution or the definitions behind the serious and other categories. The denominators and calculation methods for the term-specific percentages are not reported in the registry record.
Analysis populations and missing-data methods are not reported. The record does not state how many participants were included in each outcome analysis, whether follow-up differed by participant, or how unavailable outcomes were handled. Results for the named secondary outcomes are also not reported in the registry record for this analysis. These omissions limit assessment of precision, completeness and the relationship between the posted safety counts and the broader aims of the study.
16. Related Tutorials
17. Related Statistical Calculators
18. Sources
- ClinicalTrials.gov: Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL — NCT05507827.
- Registry record last updated 2026-09-28; status last verified 2026-09.
- Results first posted 2026-09-28.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
19. Record Summary
The registry record describes NCT05507827, a phase I trial of myeloablative conditioning, Orca-T and allogeneic donor-derived CD19/CD22-CAR T cells in adults with B-cell acute lymphoblastic leukemia. It lists a sequential design, no masking, allocation as NA, and a Bayesian dose-escalation design for CAR T-cell dosing. Listed enrollment is 22, and the record status is active, not recruiting.
The primary endpoint is the number of patients who received donor CD19/CD22-CAR T cells within 42 days, linked to manufacture of cells meeting established release specifications. The endpoint count is not reported in the registry record. One subject is noted as not receiving infusion because of active infection at the time of infusion. Dose-level adverse-event participant counts and selected serious-event terms are listed, but their interpretation is limited by the sequential, non-randomized design and unreported analysis details.
The record names seven outcome measures, including progression, graft failure, progression-free survival, overall survival and infectious disease complications, but their results are not reported in the registry record for this analysis. Statistical methods beyond the broad dose-escalation description, missing-data procedures, multiplicity handling and sample-size justification are not reported in the registry record.